DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011;34:789–794
In the “Pharmacokinetics and Dose” section (page 790) of the article listed above, the starting dose should have been 0.8 mg/day, rather than 0.8–1.6 mg/day, and the maximum dose should have been 4.8 mg/day, rather than 4.6 mg/day.
The legend for Fig. 3 should have read as follows: “Top: Kaplan-Meier plot of time to first cardiovascular (MACE) event (myocardial infarction, stroke, and death) in type 2 diabetic subjects treated with Cycloset or placebo for 52 weeks (ref. 41). Bottom: Kaplan-Meier plot of time to first cardiovascular event (myocardial infarction, stroke, hospitalization for angina or CHF, coronary revascularization, and death) in 3,070 type 2 diabetic subjects treated with Cycloset or placebo for 52 weeks (ref. 42). CVEs, cardiovascular events.”
The hazard ratio (HR) for the top curve in Fig. 3 should have been 0.45, rather than 0.55, and the 95% CI should have been 0.205–0.996, rather than 0.39–0.98.
On page 793, the sentence “Using the major adverse cardiac events (MACE) end point (myocardial infarction, stroke, and death), the HR was reduced in the Cycloset compared with placebo-treated subjects (HR 0.55, two-sided 95% CI 0.39–0.98, P < 0.05) (Fig. 3)” should have read “Using the major adverse cardiac events (MACE) end point (myocardial infarction, stroke, and death), the HR was reduced in the Cycloset compared with placebo-treated subjects (HR 0.45, two-sided 95% CI 0.205–0.996, P < 0.05) (Fig. 3).”
In Supplementary Fig. 5, the fasting TG values for each bar should have read as follows:
The online version reflects these changes.
| 7 a.m. | 9 a.m. | 2 p.m. | 7 p.m. | |
| Placebo | +35 | +32 | +28 | +23 |
| Cycloset | −37 | −38 | −43 | −24 |
| Change | −72 | −70 | −71 | −47 |